ziprasidone + mood stabilizer

A combination therapy of **ziprasidone**, a second-generation (atypical) antipsychotic of the benzisothiazolyl piperazine type, with a **mood stabilizer** (either lithium or valproate) is used in the maintenance treatment of **bipolar I disorder**, particularly for the prevention of mania. Ziprasidone acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, balancing neurotransmitters implicated in mood regulation. The combination has demonstrated superior efficacy compared to mood stabilizer monotherapy for reducing the recurrence of manic or mixed episodes and has a favorable tolerability profile, notably without significant weight gain or metabolic syndrome risk. Approved for use as adjunctive therapy, it addresses cases where monotherapy is insufficient for symptom control[1][3][7].